Drugmaker Merck says it’s bought a Swiss biotech company developing cancer drugs as part of its strategy to be a top player in cancer, one of the hottest pharmaceutical research areas. Merck & Co., based in Kenilworth, New Jersey, will pay up to $110 million upfront to OncoEthix.

Click here to read original article